source
- Parker Institute chief urges renewed focus on cancer immunotherapy after mixed results from Revolution Medicines' drugIra Mellman, who leads research at the Parker Institute for Cancer Immunotherapy, said on Sept. 16, 2026 that he felt disappointment and frustration as the industry celebrated Revolution Medicines'…
- Blackstone pledges up to $1.5 billion to fund Pfizer's obesity drug berobenatide developmentBlackstone Life Sciences has agreed to provide up to $1.5 billion to support the research and development of Pfizer's obesity candidate, berobenatide, which originated from the former Metsera progr…